Reina Sofía University Hospital, Cordoba, Spain
Alicia Vargas , María José Contreras , María De la Haba , Maria Teresa Cano , Cristina Morales-Estevez , Ignacio Porras , Gema Pulido , Pablo Flores Paco , Juan De La Haba , Enrique Aranda
Background: Anti-tumor therapy is the most frequent cause of toxic neuropathy in the Western population. Unlike its acute presentation (AN), chronic neuropathy appears during treatment and persists for more than six months after the end of chemotherapy, significantly limiting the quality of life of many patients. Although it is a drug-dependent toxicity, there is scarce evidence about its frequency and the factors that are determinant in its development. The main objetive is to know the incidence of NPCIQ as well as to identify factors that predispose to its appearance. Methods: We retrospectively selected 98 patients treated with adjuvant chemotherapy with paclitaxel (P) (80mg/m2/weekly) or oxaliplatin (O) (130 mg/m2/every 3 weeks), establishing three groups: Group A and B: Patients treated with P or O and who have developed NPCIQ and Group C patients treated with P or O and who have not developed NPCIQ.Group A P+ NPCIQ: 34 (33,3 %), Group B O+NPCIQ: 27 (26,5 %) and Group C non-NPCIQ: 37 (36,2%). Results: Of the 79 patients who developed AN, 61 (77,2%) developed NPCIQ, of these 34 due to paclitaxel and 27 due to oxaliplatin. Those patients with a body mass index > 30 or toxic habits developed NPCIQ more frequently: 24% vs 36% and 24% vs 42% (p: 0.054) respectively (Table 1).The obesity impact on NPCIQ is statistically significative for paclitaxel group (p: 0,027). Conclusions: NPCIQ is a frequent toxicity, there are avoidable factors such as obesity, smoking and alcohol that can influence its development. Recommendations aimed at avoiding overweight or the consumption of alcohol and tobacco may be useful to reduce the incidence of NPCIQ.
FACTORS | NPCIQ + | NPCIQ - |
---|---|---|
IMC > 30 | 36,1 % | 24,3 % |
Toxic habits | 42,6 % | 24,3 % |
CV risk (HT and or Diabetes) | 39,3 % | 24,3 % |
Hb < 12 or 14 | 27,1 % | 27,8 % |
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2023 ASCO Gastrointestinal Cancers Symposium
First Author: Eric Assenat
2022 ASCO Gastrointestinal Cancers Symposium
First Author: Claire Gallois
2023 ASCO Annual Meeting
First Author: Anne M. Noonan
2024 ASCO Gastrointestinal Cancers Symposium
First Author: Toru Imai